Search results
Results from the WOW.Com Content Network
[1] sGC activators, another experimental class of drugs, may be more effective than stimulators when oxidative stress is high. [1] The drugs are also considered to possibly have the potential to treat kidney disease, lung fibrosis, scleroderma, and sickle cell disease. [3] [1]
Hexokinase-I (HK-I) is an enzyme activator because it draws glucose into the glycolysis pathway. Its function is to phosphorylate glucose releasing glucose-6-phosphate (G6P) as the product. HK-I not only signals the activation of glucose into glycolysis but also maintains a low glucose concentration to facilitate glucose diffusion into the cell.
Tyrosine kinase inhibitor (TKI) with selective activity against RET, VEGFR-2 and EGFR: Medullary thyroid cancer. Diarrhoea, hypertension, QT interval prolongation, depression, electrolyte anomalies, hypothyroidism and GI perforation (uncommon). 2.3 mTOR inhibitors: Everolimus: PO: mTOR inhibitor.
"INHIBITORS, INDUCERS AND SUBSTRATES OF CYTOCHROME P450 ISOZYMES". "The Life Raft Group: Long List of Inhibitors and Inducers of CYP3A4 and CYP2D6". "DRUGBANK Online: Cytochrome P-450 Enzyme Inhibitors". "MEDICATIONS METABOLIZED BY CYTOCHROME P450 3A4" (PDF)
As of 2017, an estimated 29% of approved drugs are enzyme inhibitors [96] of which approximately one-fifth are kinase inhibitors. [96] A notable class of kinase drug targets is the receptor tyrosine kinases which are essential enzymes that regulate cell growth; their over-activation may result in cancer.
2328 14262 Ensembl ENSG00000007933 ENSMUSG00000026691 UniProt P31513 P97501 RefSeq (mRNA) NM_001002294 NM_006894 NM_001319173 NM_001319174 NM_008030 RefSeq (protein) NP_001002294 NP_001306102 NP_001306103 NP_008825 NP_032056 Location (UCSC) Chr 1: 171.09 – 171.12 Mb Chr 1: 162.78 – 162.81 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Flavin-containing monooxygenase 3 (FMO3 ...
Pharmacological myostatin inhibitors can therefore be considered exercise mimetics. [7] Creatine, a popular workout supplement, has shown some myostatin inhibitory effects in preclinical studies. [6] Many drugs in development as myostatin inhibitors also reduce the activity of related proteins such as GDF11, activins, and bone morphogenetic ...
Plasminogen activator inhibitor-1 is a serine protease, synthesized by endothelial cells, that specifically inhibits tissue plasminogen activator (tPA) and urokinase (uPA). Tissue plasminogen activator and urokinase are the activators of plasminogen and result in the breakdown of blood clots ( fibrinolysis ).